Brain Chemistry Labs

The Brain Chemistry Labs seeks to discover novel ways of preventing, diagnosing, and treating brain diseases. Our current focus is on progressive neurodegenerative diseases characterized by protein misfolds, including Alzheimers, ALS, Parkinsons, and Lewy Body disease. We are sponsoring a randomized, double-blinded, placebo-controlled Phase II clinical trial of the amino acid L-serine for the treatment of Mild Cognitive Impairment (a precursor of Alzheimers disease) at Houston Methodist Research Institute. We are currently raising funds for advanced clinical trials of L-serine for ALS, and a clinical trial for WY40687, a new drug we have discovered for advanced Parkinsons disease. We have discovered microRNA fingerprints, extracted from extracellular vesicles in the bloodstream, which are diagnostic for ALS as well as a novel metabolite which is diagnostic for early-stage Alzheimers disease. We have also discovered that naturally occurring small proteins, called cyclotides, may be useful as chemotherapy adjuvants for glioblastoma.